High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients

Georgery, Hélène; Devresse, Arnaud; Yombi, Jean‐Cyr; Belkhir, Leïla; Greef, Julien De; Scohy, Anaïs; Kanaan, Nada; Kabamba, Benoît; Morelle, Johann; Goffin, Éric

doi:10.1093/ckj/sfab101

Cited by 6 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guillaume Fernandes, MD, 1 Arnaud Devresse, PhD, 1,2 Anais Scohy, PharmD, 3 Jean Cyr Yombi, MD, 2,4 Leila Belkhir, PhD, 2,4 Julien De Greef, MD, 2,4 Martine De Meyer, MD, 2,5 Michel Mourad, PhD, 2,5 Tom Darius, PhD, 2,5 Antoine Buemi, MD, 2,5 Benoit Kabamba, MD, 2,4 Eric Goffin, MD, 1,2 and Nada Kanaan, MD 1,2 A nti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have shown good efficacy in kidney transplant candidates 1 , contrasting with disappointing results in kidney transplant recipients (KTRs). 2 However, the impact of starting immunosuppressive treatments for KTRs on anti-SARS-CoV-2 humoral immunity has been poorly investigated to date.…”

Section: Impact Of Kidney Transplantation On Humoral Immunity Against...mentioning

confidence: 99%

See 1 more Smart Citation

Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium

et al. 2021

Self Cite

View full text Add to dashboard Cite

Section: Impact Of Kidney Transplantation On Humoral Immunity Against...mentioning

confidence: 99%

“…Anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have shown good efficacy in kidney transplant candidates 1 , contrasting with disappointing results in kidney transplant recipients (KTRs). 2 However, the impact of starting immunosuppressive treatments for KTRs on anti-SARS-CoV-2 humoral immunity has been poorly investigated to date.…”

mentioning

confidence: 99%

Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…22 Based on previous studies we cannot draw any firm conclusions about differences in the effect of the vaccines on the disease course of patients on PD versus HD, because two studies found a similar effect, 23,24 while two others found higher antibody levels after vaccination in PD than in HD patients. 25,26 There are other limitations that need to be acknowledged. First, not all PD patients with COVID-19 in the participating hospitals may have been recorded in ERA-CODA.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: The clinical course of COVID-19 in peritoneal dialysis (PD) patients has so far only been analysed in relatively small, often single-centre case series. Therefore, we studied patient- and disease-related characteristics and outcomes of COVID-19 in a larger European cohort of PD patients. Methods: We used data from the European Renal Association COVID-19 Database (ERACODA) on PD and haemodialysis (HD) patients with COVID-19 (presentation between February 2020 and April 2021). Hazard ratios (HR) for mortality at 3 months were calculated using Cox proportional-hazards regression. In addition, we examined functional and mental health status among survivors at this time point as determined by their treating physician. Results: Of 216 PD patients with COVID-19, 80 (37%) were not hospitalised and 136 (63%) were hospitalised, of whom 19 (8.8%) were admitted to an intensive care unit. Mortality at 3 months for these subgroups was 18%, 40%, and 37%, respectively ( p = 0.0031). Compared with HD patients, PD patients had higher mortality (crude HR: 1.49; 95% CI: 1.33–1.66), even when adjusted for patient characteristics and disease severity (adjusted HR: 1.56; 95% CI: 1.39–1.75). Follow-up data on 67 of 146 patients who survived COVID-19 showed functional recovery to pre-COVID-19 levels in 52 (78%) and mental recovery in 58 patients (87%) at 3 months after the COVID-19 diagnosis. Conclusion: The mortality rate in the first 3 months after presentation with COVID-19 is high, especially among PD patients who were hospitalised. PD patients with COVID-19 had a higher mortality risk than HD patients. The majority of surviving patients recovered both functionally and mentally from COVID-19 within 3 months.

show abstract

“…9,85,87,89,90 These results contrast with the robust humoral response rates observed in the general population 91 and also in chronic dialysis populations. [92][93][94] Cellular response rates were also low. Bertrand et al 8 showed a 57.8% T-cell response rate in 26 KTRs after 2 doses of the BNT162b2 vaccine, using an ELISpot immunoassay.…”

Section: Immunosuppression and Anti-sars-cov-2 Vaccinesmentioning

confidence: 99%

Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients

Devresse

Greef

Yombi

et al. 2022

Transplantation Direct

Self Cite

View full text Add to dashboard Cite

Kidney transplant recipients (KTRs) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have an increased risk of mortality compared with the general population and hemodialysis patients. As these patients are immunosuppressed, it might seem obvious to attribute this excess mortality to the impaired immunity induced by immunosuppression. In line with this reasoning is the low immune response, both cellular and humoral, that KTRs mount in response to the anti-SARS-CoV-2 vaccine; however, acute respiratory distress syndrome associated with coronavirus disease 2019 is triggered by a state of inflammation and cytokine release syndrome that lead to pulmonary damage and increased mortality. In that context, immunosuppressive treatment dampening the immune response could, in theory, be potentially beneficial. This review aims at analyzing the current knowledge on the impact of immunosuppressive treatment on mortality in SARS-CoV-2-infected KTRs, the optimal management of immunosuppression in the coronavirus disease 2019 era, and the vaccine response and management in immunosuppressed KTRs.

show abstract

High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients

Cited by 6 publications

References 13 publications

Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium

Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium

Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database

Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients

Contact Info

Product

Resources

About